Following remarks made by former U.S. President Donald Trump connecting the use of Tylenol during pregnancy to autism, a notable decline in the medication’s use among expectant mothers has been observed. This trend emerged from an extensive analysis of emergency room prescribing patterns across the United States, which was recently published in the esteemed UK medical journal, The Lancet. The findings highlight how public statements by influential figures can directly impact healthcare behaviors, even amid ongoing scientific debate.
In late September, President Trump advised pregnant women to avoid Tylenol, the widely used over-the-counter pain reliever whose active ingredient is acetaminophen (also known as paracetamol). This medication is marketed by the pharmaceutical company Kenvue and is commonly recommended for managing pain and fever. Trump’s cautionary statement was supported by references to research suggesting a possible link between prenatal acetaminophen exposure and neurodevelopmental disorders, including autism spectrum conditions. However, health authorities and experts remain divided on the strength and validity of this association.
Responding to these claims, Kenvue firmly rejected any connection between Tylenol and autism, emphasizing in an official statement that acetaminophen remains the safest option for pain relief and fever reduction throughout pregnancy. The company underscored that pregnant women should not discontinue use without consulting healthcare professionals, as untreated pain and fever can also pose risks to both mother and child. This ongoing debate underscores the challenges faced by patients and providers in navigating conflicting information during pregnancy.
The study, spearheaded by Dr. Jeremy Faust, an emergency physician and Harvard professor, revealed that the initial drop in Tylenol prescriptions for pregnant women was quite pronounced but gradually diminished over several weeks. This pattern suggests that subsequent clarifications and reassurances from trusted medical organizations may have helped to counterbalance the initial fear and confusion sparked by the President’s remarks. Dr. Faust noted that the decline in Tylenol use likely left many women without effective treatment for pain or fever during emergency room visits, which could have unintended health consequences.
Specifically, the research compared prescription data from emergency departments in the three months before and after Trump’s announcement on September 22. During this period, overall Tylenol prescriptions for pregnant patients dropped by approximately 10%. The most significant decrease—around 16%—occurred among women aged 15 to 44, with the steepest weekly fall of 20% recorded in the third week following the statement. Dr. Faust expressed concern that thousands of pregnant women might have avoided necessary medication due to unfounded fears, emphasizing that acetaminophen remains the safest pain relief option available during pregnancy.
Interestingly, the study found no meaningful change in Tylenol prescriptions among non-pregnant women, indicating that the President’s comments specifically influenced pregnant patients’ behavior. Over the three months following the announcement, researchers analyzed electronic health records covering nearly 90,000 emergency visits by pregnant women, alongside more than 850,000 visits by non-pregnant women and over 8.6 million outpatient encounters involving children.
Another significant finding from the study was the sharp increase in prescriptions for leucovorin, a form of folinic acid that Trump also promoted as a potential treatment for children with autism during the same press conference. Outpatient leucovorin prescriptions for children aged 5 to 17 surged by 71% over the study period, with an initial spike of 93% in the first weeks. Although the prescription rate declined somewhat after peaking, it remained substantially higher than before the announcement. This rise reflects how public endorsements can rapidly influence medical treatment trends, even when scientific consensus is lacking.
Dr. Faust lamented the situation, highlighting the broader implications of misinformation on public trust in health and science. He warned that many families might be misled into believing that leucovorin or similar treatments could dramatically improve outcomes for children with autism, despite insufficient evidence. The study serves as a cautionary tale about the consequences of politicizing medical advice and the importance of relying on rigorous scientific evaluation.
When questioned about the study’s findings, Andrew Nixon, a spokesperson for the U.S. Department of Health and Human Services, reiterated the government’s stance by sharing a post on the social media platform X. He defended the administration’s messaging on Tylenol, framing it as part of a broader commitment to transparency and honesty in public health communication. This exchange highlights the ongoing tension between political messaging and medical expertise in shaping public perceptions and behaviors.
